Email from Leo Permission to post. I actually
Post# of 72447
Posted On: 05/19/2015 11:22:19 AM
Email from Leo
Permission to post.
I actually spend a lot of my time with answering emails. It s impossible for me to answer all the emails and calls I get. Thats why we issue press releases more often than other companies. I will even try to increase my communication with shareholders.
See my responses in Red
Can you explain why phase 3 for Brilacidin has taken so long to get approval from the FDA? Is there some problem? We needed to analyze each sample of each patient for various tests. This was something we didn't expect would be needed considering the very positive results of the trial. This has been completed now and a meeting has been scheduled with the FDA. (this was announced in our update)
With ASCO, two years later, will there be significant new information. Why has the results of phase 1 not been impressive enough to be more that just a poster, among the hundreds of others. Absolutely incorrect. The results are very impressive to say the least. Please note our shareholder update. Shareholders may not understand but concerning an ongoing Phase 1 trial, clinical efficacy may not be reported in a poster presentation. There are limits what may be presented. Shortly we will advancing kevetrin very rapidly. I will address this in an upcoming press release.
What about the article on Kevetrin that was asked of the company to write, how is that coming along? This is for a peer reviewed journal. We believe we are near to closing out this study and releasing all clinical results makes for a more powerful paper.
Has anything come out of the ECCMID for CTIX? Of course. Many companies are very interested with what we are doing and it was an opportunity to update them. We need to start a phase 3 to take it further.
Is there any of 'the best is yet to come' available for release soon, two year after ASCO 2013 the stock is now trading about 40 cents over what it was going into ASCO in 2013.
Makes no sense to me, but I am confident this will pass as we continue executing on our plan. Unfortunately we had delays but now everything is coming together. This should be evident over the next weeks. We have some of the leading compounds in the world.
Everything I state to shareholders is public information and may be shared. Best wishes, LEO
Permission to post.
I actually spend a lot of my time with answering emails. It s impossible for me to answer all the emails and calls I get. Thats why we issue press releases more often than other companies. I will even try to increase my communication with shareholders.
See my responses in Red
Can you explain why phase 3 for Brilacidin has taken so long to get approval from the FDA? Is there some problem? We needed to analyze each sample of each patient for various tests. This was something we didn't expect would be needed considering the very positive results of the trial. This has been completed now and a meeting has been scheduled with the FDA. (this was announced in our update)
With ASCO, two years later, will there be significant new information. Why has the results of phase 1 not been impressive enough to be more that just a poster, among the hundreds of others. Absolutely incorrect. The results are very impressive to say the least. Please note our shareholder update. Shareholders may not understand but concerning an ongoing Phase 1 trial, clinical efficacy may not be reported in a poster presentation. There are limits what may be presented. Shortly we will advancing kevetrin very rapidly. I will address this in an upcoming press release.
What about the article on Kevetrin that was asked of the company to write, how is that coming along? This is for a peer reviewed journal. We believe we are near to closing out this study and releasing all clinical results makes for a more powerful paper.
Has anything come out of the ECCMID for CTIX? Of course. Many companies are very interested with what we are doing and it was an opportunity to update them. We need to start a phase 3 to take it further.
Is there any of 'the best is yet to come' available for release soon, two year after ASCO 2013 the stock is now trading about 40 cents over what it was going into ASCO in 2013.
Makes no sense to me, but I am confident this will pass as we continue executing on our plan. Unfortunately we had delays but now everything is coming together. This should be evident over the next weeks. We have some of the leading compounds in the world.
Everything I state to shareholders is public information and may be shared. Best wishes, LEO
(0)
(0)